ANTIVIRAL DRUGS ADVISORY COMMITTEE
October 3, 2001
NDA 21-356, VireadÔ (tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc. Proposed for the treatment of human immunodeficiency virus (HIV) infection.
Gilead Sciences, Inc.
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
FDA Briefing Information
Briefing Documentpdf htm